Full-Time

Sr. International Product Manager

Posted on 5/30/2025

ENOVIS

ENOVIS

1,001-5,000 employees

Global medical technology company; orthopedic solutions

No salary listed

Anglet, France

In Person

Travel up to 40% for special projects.

Category
Product (2)
,
Required Skills
Power BI
Market Research
Sales
Marketing
Requirements
  • Bachelor’s degree or equivalent (Business, Marketing)
  • 5-7 years of experience in successful marketing roles in either the Medical Device or Life Sciences industries, including product development
  • Orthopedic / Musculoskeletal experience is preferred
  • Fluent in English, French and ideally one other EU language
  • Proficiency in Microsoft Office Suite, Power BI, research & insight tools
  • Demonstrated ability to hear the Voice of the Customer and align feedback with company initiatives and goals
  • Ability to work collaboratively in a cross-functional and international team environment
  • Travel willingness to travel a minimum of 20% expanding to 40% for special projects
  • Work location: France (Bayonne, Pyrénées-Atlantiques)
Responsibilities
  • Act as a subject matter expert and application expert for the assigned product portfolio.
  • Identify new product opportunities by assessing portfolio gaps, competitive landscape, and capturing VOC.
  • Lead product development initiatives to deliver successful, on-target launches that align with customer needs and market demands.
  • Utilize market research to properly inform strategy for product commercialization (needs identification, go-to-market plans, product launch strategies).
  • Create business cases to support the implementation of projects and strategic initiatives.
  • Work cross-functionally with R&D, Operations, clinical and the local sales and marketing teams to ensure on-target product success.
  • Conduct market research to develop cohesive market landscape analyses and opportunity assessments across the product portfolio.
  • Translate customer needs, market/competitive analysis into actionable strategies and tactics for the portfolio.
  • Research and assess market opportunities for new product ideas.
  • Understand competitive environment and develop appropriate product positioning.
  • Collaborate with management to establish strategic plans and objectives.
  • Work closely with the US team and local market managers to ensure alignment with market trends and customer needs to develop product strategies and roadmaps.
  • Recommend product rationalization opportunities.
  • Leverage data and competitive insights to continuously evolve understanding of the customer, the competition, market and trends.
  • Develop solid relationships with KOLs for VOC feedback, product development and new idea generation process.
  • Assist with product forecasts to operations to support product launches and inventory planning.
  • Monitor key success metrics including product launches, time-to-market, vitality index and sales of the product portfolio.
  • Develop and execute annual marketing plans to meet revenue growth expectations.
  • Develop customer segmentation, messaging, and tactics to improve marketing effectiveness.
  • Develop marketing collateral, sales support tools, and campaigns to drive growth of the portfolio.
  • Manage commercialization of newly developed products by leading speed-to-market activities, developing launch packages, collaterals and engaging market activation.
  • Support internal training and education initiatives.
  • Attend and support industry events, tradeshows and customer meetings.
Desired Qualifications
  • Notable accomplishments and experience in product management, product launch and strategic marketing in either the Life Sciences or Medical Devices industries
  • Demonstrated business acumen and critical/analytical thinking ability
  • Display of ability to navigate ambiguous environments, developing existing and new markets, and co delivering on revenue targets
  • Excellent presentation and communication skills
  • Enovis Growth Excellence system experience
  • Ability to develop solid relationships with KOLs and VOC feedback processes (if not already present)
  • Experience with Enovis portfolio or similar corporate environment
  • French language proficiency (if not covered in requirements)

Enovis develops medical devices and services to improve patient outcomes and restore mobility. It operates Prevention & Recovery with orthopedic braces, soft goods, vascular therapy, compression garments, and hot/cold therapy, and Reconstructive with joint implants and surgical tools such as Novastep. It differentiates itself through a broad clinically oriented portfolio, a global footprint, and the EGX continuous improvement program, plus the LimaCorporate acquisition expanding its transatlantic reach. Its goal is to provide better patient outcomes and mobility worldwide through sustained growth and operational excellence.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • LimaCorporate expands Enovis's reconstructive implant scale in Europe and the United States.
  • ARVIS and extremities launches are driving double-digit shoulder growth.
  • Spinamic may improve scoliosis compliance through rigid correction and breathable comfort.

What critics are saying

  • Goodwill impairment signals acquisition returns have not met capital expectations.
  • ARVIS adoption remains early, with limited procedure history outside the United States.
  • Debt maturity to 2030 still leaves refinancing pressure if growth disappoints again.

What makes ENOVIS unique

  • Enovis combines orthopedics, rehabilitation, and surgical productivity across two segments.
  • Its DonJoy, Aircast, Exos, and Chattanooga brands have broad clinician recognition.
  • EGX emphasizes continuous operational improvement across more than 30 global facilities.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at ENOVIS who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Paid Holidays

Legal Services

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

32%
Yahoo Finance
Feb 28th, 2026
Enovis reports strong revenue growth and new device uptake despite $1.18B goodwill impairment

Enovis Corporation has reported strong organic revenue growth driven by new product launches, including the Nebula Stem and OrthoDrive Impactor, which have seen rapid market uptake. The medical technology company's devices are gaining traction with surgeons and hospitals. However, Enovis recorded a significant goodwill impairment charge in its fourth quarter and full-year results, affecting its balance sheet. The impairment raises questions about returns from previous acquisitions and future capital allocation strategy. Trading at $25.47, Enovis shares are approximately 44% below the analyst price target of $45.18. The company currently shows a loss of $1.18 billion and trades at a forward price-to-earnings ratio of 25.73 times. Investors are advised to monitor how product adoption and procedure volumes affect future cash flow.

Yahoo Finance
Feb 26th, 2026
Enovis stock jumps 12.6% on strong 2026 earnings forecast despite Q4 revenue miss

Enovis Corporation shares jumped 12.6% in morning trading after the medical technology company reported mixed fourth-quarter results but issued a strong earnings forecast for 2026. Whilst quarterly revenue of approximately $576 million missed expectations, adjusted earnings per share of $0.95 beat analyst estimates. The stock surge was driven by Enovis's 2026 earnings guidance of $3.52 to $3.73 per share, with the midpoint significantly exceeding analyst projections. This positive profit outlook overshadowed the revenue shortfall. Enovis shares have experienced high volatility, with 26 moves exceeding 5% over the past year. The stock is down 6.6% year-to-date and trading 38.1% below its 52-week high of $40 from March 2025.

Yahoo Finance
Feb 26th, 2026
Enovis reports $520.6M Q4 loss despite adjusted earnings of 95 cents per share

Enovis Corporation reported a fourth-quarter loss of $520.6 million, or $9.10 per share. The Wilmington, Delaware-based manufacturing and engineering company posted adjusted earnings of 95 cents per share, excluding asset impairment and non-recurring costs. Revenue for the quarter reached $575.8 million. For the full year, Enovis reported a loss of $1.18 billion, or $20.75 per share, on revenue of $2.25 billion.

Yahoo Finance
Jan 23rd, 2026
BTIG initiates Enovis with $41 target as orthopedic tech firm eyes growth from new product launches

Enovis Corporation has received positive analyst coverage, with BTIG initiating a Buy rating and $41 price target on 6 January. The orthopedic care company is expected to see accelerated growth in 2026 driven by new product launches across extremities, hips and knees. BTIG highlighted the company's consistent mid-to-high single-digit organic revenue growth in its Reconstruction and Prevention & Recovery segments. The higher-growth Reconstruction business is expected to drive margins whilst the mature Prevention & Recovery segment delivers steady cash flow. UBS maintained its Buy rating but lowered its price target to $50 from $57, projecting sales of $2.26 billion in 2025, $2.37 billion in 2026 and $2.52 billion in 2027.

TradingView
Dec 10th, 2025
Enovis secures $700M term loan and $1.1B credit facility, extends maturity to 2030

Enovis Corp has entered Amendment No. 3 to its credit agreement on 8 December, extending the loan maturity date to 8 December 2030. The amended agreement provides a revolving credit facility of up to $1.1 billion and a term loan facility of $700 million. The company used term loan proceeds to repay $335 million from its revolving facility. The amendment restructures Enovis's debt arrangements, providing the medical technology company with extended financing flexibility through the end of the decade.

INACTIVE